TRENDING:

In Less Than 2 Hours, Airing Surpasses $100,000 Goal to...
Which Patients Are Good Candidates for Inspire Upper Ai...
Philips Amara View CPAP Mask
  • Privacy Policy
  • Terms of Service
  • Copyright
Sleep Review
  • Sleep Disorders
    • Breathing Disorders
    • Insomnia
    • Hypersomnias
    • Movement Disorders
    • Circadian Rhythm Disorders
    • Parasomnias
  • Sleep Diagnostics
    • Screeners
    • In-Lab Tests
    • Home Based/Out of Lab
    • Connected Care
    • Consumer Sleep Tracking
  • Sleep Treatments
    • Therapy Devices
    • Pharmaceuticals
    • Surgeries & Procedures
    • Behavioral Sleep Medicine
  • Sleep Health
    • Parameters
    • Demographics
    • Sleep & Body Systems
    • Prevailing Attitudes
  • Practice Management
    • Money
    • Laws & Regulations
    • Marketing
    • Human Resources
    • Continuing Education
  • Edition Archive

Select Page

Category: Non-24-Hour Disorder

Non-24-Hour Disorder

Latest
Some States Extend HETLIOZ Coverage to Patients With Non-24 Who Are Not Totally Blind

Some States Extend HETLIOZ Coverage to Patients With Non-24 Who Are Not Totally Blind

A patient filed a federal lawsuit challenging the unlawfulness of Colorado Medicaid's prior authorization criteria for HETLIOZ coverage.

  • The Lancet: Hetlioz, Taken Daily at Fixed Time, Promotes Master Body Clock Entrainment

  • What You Need to Know About Non-24

  • In Europe, Hetlioz Receives Positive CHMP Opinion

  • National Organization for Rare Disorders to Honor Hetlioz

  • In Q42014, Hetlioz Sales Increase 15% Compared to Q32014

  • Hetlioz US Sales Grow to $5.2 Million in First Full Quarter Since Launch

Non-24-Hour Disorder

Latest

More Than 420 Prescriptions Written for Hetlioz

“We are encouraged by the early positive reception of Hetlioz by patients, physicians, and payors. We look forward to more patients benefiting from Hetlioz in the coming months and years,” says Mihael Polymeropoulos...

  • European Medicines Agency Accepts Hetlioz Marketing Authorization Application

    European Medicines Agency Accepts Hetlioz Marketing Authorization Application

  • Vanda Reports Net Loss of $26.5 Million Due in Part to Hetlioz Launch Expenses

    Vanda Reports Net Loss of $26.5 Million Due in Part to Hetlioz Launch Expenses

  • Blind Adventurer Raises Awareness of Non-24 with Vanda Pharmaceuticals

    Blind Adventurer Raises Awareness of Non-24 with Vanda Pharmaceuticals

  • FDA Approves Hetlioz for Non-24-Hour Disorder

    FDA Approves Hetlioz for Non-24-Hour Disorder

  • Tasimelteon Resets Body Clock in Non-24-Hour Sleep-Wake Disorder

    Tasimelteon Resets Body Clock in Non-24-Hour Sleep-Wake Disorder

Non-24-Hour Disorder

Latest
Sorry, No Posts Found
Sorry, No Posts Found

MEDQOR INFORMATION SERVICES NETWORK

  • 24×7
  • Axis Imaging News
  • Clinical Lab Products
  • Hearing Review
  • Orthodontic Products
  • Physical Therapy Products
  • Plastic Surgery Practice
  • Rehab Management
  • RT: For Decision Makers in Respiratory Care
  • Sleep Review

Resources

  • Edition Archive
  • Events Calendar
  • Featured Reports
  • Podcasts
  • Webinars
  • White Papers
  • Videos

Helpful Links

  • Marketing Solutions
  • Subscribe
  • Submit an Article
  • Editorial Advisory Board
  • Contact Us

Designed by Elegant Themes | Powered by WordPress

  • Privacy Policy
  • Terms of Service
  • Copyright